Disease · MONDO_0020121
Targets124
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 124
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| DMD | Dystrophin pre-mRNA | 4 | Dystrophin pre-mRNA positive modulator | Approval | https://conductscience.org/library/genes/1756 | Drugs and targets |
| MSTN | Growth/differentiation factor 8 | 2 | Growth/differentiation factor 8 inhibitor | Phase 2 | https://conductscience.org/library/genes/2660 | Drugs and targets |
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | 2 | Phosphodiesterase 5A inhibitor | Phase 2 | https://conductscience.org/library/genes/8654 | Drugs and targets |
| ADRM1 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 1 | https://conductscience.org/library/genes/11047 | Drugs and targets |
| FAU | 80S Ribosome | 1 | 80S Ribosome modulator | Phase 2 | https://conductscience.org/library/genes/2197 | Drugs and targets |
| MAOA | Monoamine oxidase | 1 | Monoamine oxidase inhibitor | Preclinical | https://conductscience.org/library/genes/4128 | Drugs and targets |
| MAOB | Monoamine oxidase | 1 | Monoamine oxidase inhibitor | Preclinical | https://conductscience.org/library/genes/4129 | Drugs and targets |
| MAS1 | Proto-oncogene Mas | 1 | Proto-oncogene Mas agonist | Phase 1 | https://conductscience.org/library/genes/4142 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor agonist | Approval | https://conductscience.org/library/genes/2908 | Drugs and targets |
| NR3C2 | Mineralocorticoid receptor | 1 | Mineralocorticoid receptor antagonist | Unknown | https://conductscience.org/library/genes/4306 | Drugs and targets |
| PSMA1 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 1 | https://conductscience.org/library/genes/5682 | Drugs and targets |
| PSMA2 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 1 | https://conductscience.org/library/genes/5683 | Drugs and targets |
| PSMA3 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 1 | https://conductscience.org/library/genes/5684 | Drugs and targets |
| PSMA4 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 1 | https://conductscience.org/library/genes/5685 | Drugs and targets |
| PSMA5 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 1 | https://conductscience.org/library/genes/5686 | Drugs and targets |
| PSMA6 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 1 | https://conductscience.org/library/genes/5687 | Drugs and targets |
| PSMA7 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 1 | https://conductscience.org/library/genes/5688 | Drugs and targets |
| PSMA8 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 1 | https://conductscience.org/library/genes/143471 | Drugs and targets |
| PSMB1 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 1 | https://conductscience.org/library/genes/5689 | Drugs and targets |
| PSMB10 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 1 | https://conductscience.org/library/genes/5699 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020121/targets